Skip to main content
SpringerLink
Log in

Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient

  • Case Report
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Osimertinib is the best treatment choice for patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) whose disease progresses on a first- or second-generation EGFR-tyrosine kinase inhibitor due to acquired T790M mutation. On the other hand, there is a lack of therapeutic strategies with proven efficacy at the time of progression on osimertinib. If not administered previously, platinum-based chemotherapy can provide some clinical benefit, while immunotherapy does not seem to work in this setting. Here, we report on a unique case of response to osimertinib rechallenge after intervening chemotherapy in an EGFR T790M-positive NSCLC patient pretreated with the sequence erlotinib–osimertinib.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–40.

    Article  CAS  Google Scholar 

  2. Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009;27(10):1667–74.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Cappuzzo F, Morabito A, Normanno N, et al. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer. 2016;99:31–7.

    Article  PubMed  Google Scholar 

  4. Xia GH, Zeng Y, Fang Y, et al. Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI. Cancer Biol Med. 2014;11(4):270–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Landi L, Tiseo M, Chiari R, et al. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. Clin Lung Cancer. 2014;15(6):411–7.

    Article  CAS  PubMed  Google Scholar 

  6. Tang ZH, Lu JJ. Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Lett. 2018;420:242–6.

    Article  CAS  PubMed  Google Scholar 

  7. Oxnard G, Hu Y, Mileham K, et al. Osimertinib resistance mediated by loss of EGFR T790M is associated with early resistance and competing resistance mechanisms. J Thorac Oncol. 2017;12:S1767–8 (abstract).

    Article  Google Scholar 

  8. Arulananda S, Do H, Musafer A, et al. Combination osimertinib and gefitinib in C797S and T790M EGFR-mutated non-small cell lung cancer. J Thorac Oncol. 2017;12(11):1728–32.

    Article  Google Scholar 

  9. Wang Z, Yang JJ, Huang J, et al. Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKIs and shifts allelic configuration at resistance. J Thorac Oncol. 2017;12(11):1723–7.

    Article  PubMed  Google Scholar 

  10. Canale M, Petracci E, Delmonte A, et al. Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. Clin Cancer Res. 2017;23(9):2195–202.

    Article  CAS  PubMed  Google Scholar 

  11. Haratani K, Hayashi H, Tanaka T, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol. 2017;28(7):1532–9.

    Article  CAS  PubMed  Google Scholar 

  12. Oda N, Ichihara E, Hotta K, et al. Phase II study of the EGFR-TKI rechallenge with afatinib in patients with advanced NSCLC harboring sensitive EGFR mutation without T790M: Okayama Lung Cancer Study Group trial OLCSG 1403. Clin Lung Cancer. 2017;18(2):241–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the patient for providing written informed consent for publication of his case.

Author information

Authors and Affiliations

  1. Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Piazzale Menghini, 1, 06129, Perugia, Italy

    Giulio Metro, Sara Baglivo, Annamaria Siggillino, Vienna Ludovini & Rita Chiari

  2. Department of Diagnostic Imaging, University of Perugia, Perugia, Italy

    Alberto Rebonato

  3. Anatomic Pathology and Histology Section, Department of Experimental Medicine, University of Perugia, Perugia, Italy

    Guido Bellezza

Authors
  1. Giulio Metro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sara Baglivo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Annamaria Siggillino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vienna Ludovini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rita Chiari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alberto Rebonato
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Guido Bellezza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giulio Metro.

Ethics declarations

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest

The authors declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Metro, G., Baglivo, S., Siggillino, A. et al. Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. Clin Drug Investig 38, 983–987 (2018). https://doi.org/10.1007/s40261-018-0691-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-018-0691-8

Search

Navigation